From: Hypertension, renin-angiotensin-aldosterone-system-blocking agents, and COVID-19
Characteristic | Total (n = 3,788) | Hypertension (n = 1,190) | Non-hypertension (n = 2,598) | P-value |
---|---|---|---|---|
Age (yr) | 52.1 ± 15.1 | 63.9 ± 14.0 | 46.7 ± 12.3 | < 0.001 |
Age distribution (yr) | < 0.001 | |||
30‒39 | 970 (25.6) | 57 (4.8) | 913 (35.1) | |
40‒49 | 860 (22.7) | 142 (11.9) | 718 (27.6) | |
50‒59 | 808 (21.3) | 259 (21.8) | 549 (21.1) | |
60‒69 | 570 (15.0) | 289 (24.3) | 281 (10.8) | |
70‒79 | 374 (9.9) | 271 (22.8) | 103 (4.0) | |
80–89 | 180 (4.8) | 151 (12.7) | 29 (1.1) | |
≥ 90 | 26 (0.7) | 21 (1.8) | 5 (0.2) | |
Male sex | 1,692 (44.7) | 605 (50.8) | 1,087 (41.8) | < 0.001 |
Comorbidity | ||||
Diabetes | 655 (17.3) | 483 (40.6) | 172 (6.6) | < 0.001 |
Dyslipidemia | 1,103 (29.1) | 716 (60.2) | 387 (14.9) | < 0.001 |
Chronic kidney disease | 234 (6.2) | 213 (18.0) | 21 (0.8) | < 0.001 |
Chronic obstructive pulmonary disease | 387 (10.2) | 213 (18.0) | 174 (6.7) | < 0.001 |
Cancer | 313 (8.3) | 153 (12.9) | 160 (6.2) | < 0.001 |
Cardiovascular disease | 513 (13.5) | 429 (36.1) | 84 (3.2) | < 0.001 |
Ischemic heart disease | 269 (7.1) | 226 (19.0) | 43 (1.7) | < 0.001 |
Myocardial infarction | 36 (1.0) | 34 (2.9) | 2 (0.1) | < 0.001 |
Stroke | 185 (4.9) | 163 (13.7) | 22 (0.8) | < 0.001 |
Congestive heart failure | 223 (5.9) | 191 (16.1) | 32 (1.2) | < 0.001 |